Mining & Metals
Satellos Bioscience to Present New Data at International Congress Next Month
Satellos Bioscience (MSCL.TO) will present new data from its SAT-3247 clinical development program at the 19th International Congress on Neuromuscular Diseases in Italy next month.The biotechnology company, which is developing therapies to treat degenerative muscle diseases, saidpresentations will include a poster highlighting six-month follow-up data from participants who completed the Phase 1b SAT-3247 CL-101 trial and enrolled in the current Phase 2 Trailhead trial.SAT-3247 is an oral, small molecule drug candidate being developed as a treatment approach to regenerating skeletal muscle lost in Duchenne muscular dystrophy and other degenerative muscle diseases or injury conditions.Price: $8.50, Change: $+0.57, Percent Change: +7.19%
$MSCL.TO
